Byambasuren Oyungerel, Sanders Sharon, Beller Elaine, Glasziou Paul
Centre for Research in Evidence-Based Practice (CREBP), Bond University, Robina, QLD Australia.
NPJ Digit Med. 2018 May 9;1:12. doi: 10.1038/s41746-018-0021-9. eCollection 2018.
Mobile health apps aimed towards patients are an emerging field of mHealth. Their potential for improving self-management of chronic conditions is significant. Here, we propose a concept of "prescribable" mHealth apps, defined as apps that are currently available, proven effective, and preferably stand-alone, i.e., that do not require dedicated central servers and continuous monitoring by medical professionals. Our objectives were to conduct an overview of systematic reviews to identify such apps, assess the evidence of their effectiveness, and to determine the gaps and limitations in mHealth app research. We searched four databases from 2008 onwards and the Journal of Medical Internet Research for systematic reviews of randomized controlled trials (RCTs) of stand-alone health apps. We identified 6 systematic reviews including 23 RCTs evaluating 22 available apps that mostly addressed diabetes, mental health and obesity. Most trials were pilots with small sample size and of short duration. Risk of bias of the included reviews and trials was high. Eleven of the 23 trials showed a meaningful effect on health or surrogate outcomes attributable to apps. In conclusion, we identified only a small number of currently available stand-alone apps that have been evaluated in RCTs. The overall low quality of the evidence of effectiveness greatly limits the prescribability of health apps. mHealth apps need to be evaluated by more robust RCTs that report between-group differences before becoming prescribable. Systematic reviews should incorporate sensitivity analysis of trials with high risk of bias to better summarize the evidence, and should adhere to the relevant reporting guideline.
面向患者的移动健康应用程序是移动医疗的一个新兴领域。它们在改善慢性病自我管理方面具有巨大潜力。在此,我们提出“可开处方的”移动医疗应用程序的概念,定义为目前已有的、经证实有效的且最好是独立的应用程序,即不需要专用中央服务器和医疗专业人员持续监测的应用程序。我们的目标是对系统评价进行综述,以识别此类应用程序,评估其有效性证据,并确定移动医疗应用程序研究中的差距和局限性。我们检索了从2008年起的四个数据库以及《医学互联网研究杂志》,以查找对独立健康应用程序随机对照试验(RCT)的系统评价。我们识别出6项系统评价,包括23项RCT,评估了22款可用应用程序,这些应用程序大多涉及糖尿病、心理健康和肥胖问题。大多数试验是样本量小且持续时间短的试点试验。纳入的评价和试验的偏倚风险很高。23项试验中有11项显示应用程序对健康或替代结局有显著影响。总之,我们仅识别出少数几款目前已有的、在RCT中得到评估的独立应用程序。有效性证据的总体质量较低,极大地限制了健康应用程序的可开处方性。在移动医疗应用程序具有可开处方性之前,需要通过更严格的RCT进行评估,这些RCT应报告组间差异。系统评价应纳入对偏倚风险高的试验的敏感性分析,以更好地总结证据,并应遵循相关报告指南。